At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 324 enrolled
Drug / intervention
Mometasone furoate nasal spray (MFNS) +1 moredrug
Likely dose
Mometasone furoate nasal spray (MFNS) 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)
In Brief
A Phase 3 clinical trial evaluating Mometasone furoate nasal spray (MFNS) and Matching placebo nasal spray for Allergic Rhinitis. Completed, enrolled 324 participants.
Detailed Summary
This study seeks to prospectively demonstrate that Nasonex is better than placebo in relieving nasal congestion in patients with seasonal allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedAug 2008
Primary CompletionOct 2008
TodayJul 2026
First PostedAug 12, 2008
Enrollment StartJul 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.9 years ago
Interventions
Mometasone furoate nasal spray (MFNS)drug
MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
Matching placebo nasal spraydrug
Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days